Core Viewpoint - The Gross Law Firm has announced a class action lawsuit against RxSight, Inc. for allegedly misleading shareholders regarding the company's performance and financial guidance during a specified class period [2][4]. Summary by Relevant Sections Allegations - The complaint claims that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the company overstated the demand for its products [2]. - As a result of these issues, RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants about the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Class Period and Deadlines - The class period for the lawsuit is from November 7, 2024, to July 8, 2025 [2]. - Shareholders are encouraged to register for the class action by September 22, 2025, to be eligible for potential recovery [3]. Next Steps for Shareholders - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased RxSight securities between November 7, 2024, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Allegations Against RxSight - The lawsuit alleges that throughout the Class Period, RxSight's management made false and misleading statements regarding the company's sales and product demand, which ultimately misled investors [5]. - Specific claims include that RxSight faced "adoption challenges" and structural issues leading to declines in sales, and that the company was unlikely to meet its previously issued financial guidance for fiscal year 2025 [5].

Core Viewpoint - The RxSight class action lawsuit alleges that the company and its executives made misleading statements regarding the company's performance and financial guidance, leading to significant stock price declines [1][4][5]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company focused on the research, development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery [3]. Allegations of the Lawsuit - The lawsuit claims that during the class period, RxSight faced "adoption challenges" and structural issues that resulted in declining sales and utilization of its products [4]. - It is alleged that RxSight overstated the demand for its products, which contributed to the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - Following the release of preliminary second-quarter financial results on July 8, 2025, which showed significant declines in Light Delivery Device (LDD) sales and overall revenue, RxSight lowered its full-year guidance by approximately $42.5 million at the midpoint [5]. Financial Impact - The announcement of the lowered guidance and the challenges faced by RxSight led to a nearly 38% drop in the company's stock price [5].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - RxSight, Inc. specializes in the manufacture and sale of light adjustable intraocular lenses used in cataract surgery, with its main product being the Light Adjustable Lens (LAL) [3]. Financial Performance and Issues - The company previously reported strong sales of LAL and Light Delivery Devices (LDD) but failed to disclose "adoption challenges" and a slowdown in LAL utilization that began in 2024 [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast due to a "softening" market, leading to a stock price decline of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulting in another 38% drop in stock price, from $12.79 to $7.95 per share [6].

Accessibility StatementSkip Navigation SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the RxSight class action lawsuit – captioned Makaveev v. RxSight, Inc., No. 25-cv-01596 (C.D. Cal.) – seeks to represent purchasers or acquirers of RxSight, Inc. (NASDAQ: RXST) securities and charges RxSight as well as certain of RxSight's executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead ...

Core Viewpoint - A class action lawsuit has been filed against RxSight, Inc. for allegedly making false statements and failing to disclose significant challenges affecting its business performance, leading to a substantial drop in stock price [3][4]. Company Overview - RxSight, Inc. is a commercial-stage medical technology company that specializes in developing, manufacturing, and selling light adjustable intraocular lenses (LAL) used in cataract surgery [2]. Allegations of the Lawsuit - The lawsuit claims that RxSight faced adoption challenges and structural issues that negatively impacted sales and utilization of its products [3]. - It is alleged that the demand for RxSight's products was overstated, and the company was unlikely to meet its previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported preliminary second-quarter 2025 financial results showing significant declines in Light Delivery Device (LDD) sales, LAL utilization, and overall revenue [4]. - The company reduced its full-year 2025 guidance by approximately $42.5 million at the midpoint, with the CEO acknowledging that adoption challenges were a primary reason for the stall in LDD sales [4]. - Following this announcement, RxSight's stock price fell nearly 38% [4].

Core Viewpoint - RxSight, Inc. is under investigation by Faruqi & Faruqi, LLP for potential claims related to its securities, indicating possible legal challenges ahead for the company [1] Company Summary - RxSight, Inc. is listed on NASDAQ under the ticker RXST [1] - The investigation is being conducted by Faruqi & Faruqi, a prominent national securities law firm with a history of recovering substantial amounts for investors [1] Legal Context - Faruqi & Faruqi has been operational since 1995 and has offices in New York, Pennsylvania, California, and Georgia [1] - The firm has successfully recovered hundreds of millions of dollars for investors, highlighting its experience and capability in handling securities-related claims [1]

Core Points - Berger Montague PC is investigating potential securities fraud claims against RxSight, Inc. following a federal securities class action lawsuit [1][2] - The lawsuit alleges that RxSight faced "adoption challenges" and structural issues leading to declines in sales and utilization, and that the demand for its products was overstated [2] - It is claimed that RxSight is unlikely to meet its previously issued financial guidance for fiscal year 2025 [2] Company Information - RxSight, Inc. is publicly traded on NASDAQ under the ticker RXST [1] - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, with a deadline for investors to seek lead plaintiff status by September 22, 2025 [3] - Berger Montague has a long history in securities class action litigation, having represented investors for over five decades [4]

NEW YORK, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/rxsight-inc-lawsuit ...

Market Overview - The cataract market is the largest surgical market in the U.S. [2] - There has been a decrease in overall cataract surgeries at the beginning of the year, which is a notable trend not seen for a while [2] - Despite demographic trends suggesting low single-digit growth, the reasons for the decrease in surgeries remain unclear [3] Premium Segment Insights - The premium segment of the cataract market has shown more stability compared to the overall market [3] - The demographic for cataract surgery typically involves patients aged 60 and above [3]